Skip to main content

Table 1 Overview of included study measures and scales in the TRACK-PD study

From: The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson’s disease

Method

Outcome

Scales

Visit 1 (Baseline)

Visit 2 (2 Years)˟

Visit 3 (4 Years)˟

Assessed by trial assessor

Motor functioning in ‘ON’ state

MDS-UPDRS III (including H&Y stage)

X*

X*

X*

MDS-UPDRS IV

X*

X*

X*

Neuropsychological symptoms

MoCA

X

X

X

Phonemic and semantic fluency

X

X

X

15 Words Test

X

X

X

Benton Judgment of Line Orientation

X

X

X

Letter Number Sequencing

X

X

X

Symbol Digit Modalities Test

X

X

X

MDS-UPDRS I

X*

X*

X*

Demographics and lifestyle

Medical history

X

X

X

Medication

X

X

X

Biospecimen

EDTA Plasma (DNA)

X

  

Pax Gene (RNA)

X

  

Brain structure and function

Resting-state functional MRI

X

X

X

Structural MRI (T1, T2*, neuromelanin, DWI)

X

X

X

Wearable sensors

Motor parameters

IMU including 3-axis accelerometer and 3-axis gyroscope

X

X

X

Self-reported patient questionnaires

Neuropsychiatric symptoms

BDI

X

X

X

QUIP-RS

X

X

X

PAS

X

X

X

Quality of life

PDQ-8

X*

X*

X*

Autonomic symptoms

SCOPA-AUT

X

X

X

Sleep disorders

RBDQ

X

X

X

Various

MDS-UPDRS II

X*

X*

X*

  1. BDI Beck Depression Inventory, HC healthy controls, H&Y Hoehn and Yahr scale, IMU Inertial Measurement Unit, MDS-UPDRS Movement Disorders Society Unified Parkinson Disease Rating Scale, MoCA Montreal Cognitive Assessment, NPA Neuropsychological assessment, PAS Parkinson Anxiety Scale, PD Parkinson’s disease patients, PDQ-8 Parkinson’s Disease Questionnaire, QUIP-RS Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease, RBDSQ REM-sleep behaviour disorder screening questionnaire, SCOPA-AUT Scales for Outcomes in Parkinson’s Disease - Autonomic dysfunction questionnaire
  2. ˟ ± 60 days; * Only for PD patients